好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Association of Cortical Superficial Siderosis with Poor Functional Outcomes Following Cerebral Amyloid Angiopathy-Related Hemorrhage
Cerebrovascular Disease and Interventional Neurology
S2 - Advances in Stroke Imaging and Biomarkers (1:36 PM-1:48 PM)
003

The recent update to the Boston criteria for CAA adds two neuroimaging markers to increase the sensitivity of CAA detection: multispot white matter hyperintensity (WMH) pattern and severe centrum semiovale enlarged perivascular spaces (CSO EPVS). While these non-hemorrhagic markers, together with well-established hemorrhagic markers such as lobar cerebral microbleeds (CMBs) and cortical superficial siderosis (cSS), increases the likelihood of underlying CAA in patients with ICH, it is unclear whether they impact clinical outcomes.

We evaluated whether the presence of hemorrhagic or non-hemorrhagic neuroimaging markers have any prognostic impact in cerebral amyloid angiopathy (CAA)-related intracerebral hemorrhage (ICH).

To diagnose CAA, brain MRIs from a prospective database of consecutive non-traumatic ICH patients admitted to a tertiary care center were reviewed for the presence of CMBs, cSS, multispot WMH pattern, and CSO EPVS. Clinical and neuroimaging predictors of an unfavorable discharge outcome (modified Rankin score ≥ 4) were assessed in univariable and multivariable models.

Between 2003 and 2019, 645 (36%) of 1,791 ICH patients were diagnosed with CAA (mean age 74±11 years, 49% female) based on available MRIs (performed in 72%). Lobar CMBs occurred in 326 (51%) patients, cSS occurred in 197 (31%), multispot WMH pattern occurred in 123 (19%), and severe CSO EPVS occurred in 156 (24%). In univariable analyses, age, hypertension, diabetes, ischemic stroke history, dementia, admission Glasgow Coma Scale (GCS) scores, intubation, external ventricular drain placement, hematoma evacuation, intraventricular extension, and cSS were associated with an unfavorable discharge outcome (all p < 0.05). When these variables were entered into a multivariable model subjected to backward elimination, age, hypertension, dementia, GCS score, intubation, intraventricular extension, and cSS (aOR 1.75, 95% CI 1.07–2.88) remained significantly associated with an unfavorable outcome.

Although hemorrhagic and non-hemorrhagic neuroimaging markers are common in CAA patients with ICH, only cSS is significantly associated with unfavorable clinical outcomes.

Authors/Disclosures
Alvin Das, MD (Beth Israel Deaconess Medical Center)
PRESENTER
Dr. Das has nothing to disclose.
Avia Abramovitz Ms. Abramovitz has nothing to disclose.
Elif Gokcal Elif Gokcal has nothing to disclose.
Ofer Rotschild Ofer Rotschild has nothing to disclose.
Robert W. Regenhardt, MD, PhD Dr. Regenhardt has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genomadix. Dr. Regenhardt has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Rapid Medical. Dr. Regenhardt has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Johnson and Bell Trial Lawyers. Dr. Regenhardt has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Buckley, Theroux, Kline, & Cooley Trial Lawyers. The institution of Dr. Regenhardt has received research support from National Institutes of Health. The institution of Dr. Regenhardt has received research support from Society of Vascular and Interventional Neurology. The institution of Dr. Regenhardt has received research support from Heitman Foundation.
Magdy H. Selim, MD, PhD (Beth Israel Deaconess Med. Ctr.) Dr. Selim has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MedRhythms Inc..
Anand Viswanathan, MD (Massachusetts General Hospital) Dr. Viswanathan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alnylam Pharmaceuticals. Dr. Viswanathan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Viswanathan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche Pharmaceuticals.
Joshua Goldstein (Massachusetts General Hospital) Joshua Goldstein has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CSL Behring. The institution of Joshua Goldstein has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Octapharma. Joshua Goldstein has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astrazeneca. The institution of Joshua Goldstein has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. The institution of Joshua Goldstein has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Octapharma. Joshua Goldstein has stock in NControl. Joshua Goldstein has stock in Cayuga. The institution of Joshua Goldstein has received research support from Pfizer. The institution of Joshua Goldstein has received research support from Takeda.
Jonathan Rosand, MD (Massachusetts General Hospital) Dr. Rosand has received personal compensation for serving as an employee of Massachusetts General Hospital. Dr. Rosand has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly and Co. Dr. Rosand has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Rosand has received personal compensation in the range of $50,000-$99,999 for serving as an Expert Witness for National Football League. The institution of Dr. Rosand has received research support from NIH. The institution of Dr. Rosand has received research support from American Heart Association. Dr. Rosand has received personal compensation in the range of $0-$499 for serving as a Peer reviewer with National Institutes of Health. Dr. Rosand has a non-compensated relationship as a Trustee with Columbia University that is relevant to AAN interests or activities.
Steven M. Greenberg, MD, PhD, FAAN Dr. Greenberg has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bayer. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myers Squib. The institution of Dr. Greenberg has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alnylam. Dr. Greenberg has received research support from National Institutes of Health. Dr. Greenberg has received publishing royalties from a publication relating to health care.
Edip M. Gurol, MD (Massachusetts General Hospital) The institution of Dr. Gurol has received research support from NIH/NINDS. The institution of Dr. Gurol has received research support from Boston Scientific Corporation. The institution of Dr. Gurol has received research support from AVID (a wholly owned subsidiary of Eli Lilly). The institution of Dr. Gurol has received research support from Pfizer.